CR9386A - Derivados de ciclopentapiridina y tetrahidroquinolina - Google Patents
Derivados de ciclopentapiridina y tetrahidroquinolinaInfo
- Publication number
- CR9386A CR9386A CR9386A CR9386A CR9386A CR 9386 A CR9386 A CR 9386A CR 9386 A CR9386 A CR 9386A CR 9386 A CR9386 A CR 9386A CR 9386 A CR9386 A CR 9386A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cyclopentapiridine
- tetrahydroquinoline derivatives
- tetrahydroquinoline
- cyclopenta
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
En este documento se describen compuestos 6,7-dihidro-5H-ciclopenta[b]piridina y 5,6,7,8-tetrahidroquinolina de Formula (I), incluyendo sales, hidratos y solvatos de los mismos, que actuan como ligandos del receptor 5-HT2 y sus usos en el tratamiento de enfermedades relacionadas con la activacion de los receptores 5-HT2c.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66718405P | 2005-03-31 | 2005-03-31 | |
US76215906P | 2006-01-26 | 2006-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9386A true CR9386A (es) | 2007-10-02 |
Family
ID=36218589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9386A CR9386A (es) | 2005-03-31 | 2007-09-19 | Derivados de ciclopentapiridina y tetrahidroquinolina |
Country Status (24)
Country | Link |
---|---|
US (1) | US7507732B2 (es) |
EP (1) | EP1869000A1 (es) |
JP (1) | JP4318744B2 (es) |
KR (1) | KR100894006B1 (es) |
AP (1) | AP2007004144A0 (es) |
AR (1) | AR054021A1 (es) |
AU (1) | AU2006228378A1 (es) |
BR (1) | BRPI0609268A2 (es) |
CA (1) | CA2602348C (es) |
CR (1) | CR9386A (es) |
DO (1) | DOP2006000076A (es) |
EA (1) | EA200701853A1 (es) |
GT (1) | GT200600128A (es) |
IL (1) | IL185492A0 (es) |
MA (1) | MA29354B1 (es) |
MX (1) | MX2007012082A (es) |
NL (1) | NL1031473C2 (es) |
NO (1) | NO20074368L (es) |
NZ (1) | NZ560917A (es) |
PE (1) | PE20061333A1 (es) |
TN (1) | TNSN07367A1 (es) |
TW (1) | TW200722423A (es) |
UY (1) | UY29446A1 (es) |
WO (1) | WO2006103511A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7638519B2 (en) | 2003-12-23 | 2009-12-29 | Myogen, Inc. | Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease |
TW200633721A (en) * | 2004-12-14 | 2006-10-01 | Shionogi & Co | A pharmaceutical composition for treating constipation |
WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
ATE496894T1 (de) * | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
CA2669590A1 (en) * | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | 2-aminoquinolines as 5-ht(5a) receptor antagonists |
EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
CN101959864A (zh) | 2008-03-07 | 2011-01-26 | 弗·哈夫曼-拉罗切有限公司 | 2-氨基喹啉衍生物 |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CA2771278A1 (en) | 2009-08-26 | 2011-03-03 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
US20120253036A1 (en) | 2009-12-11 | 2012-10-04 | Yukinori Nagakura | Agent for treating fibromyalgia |
US8674218B2 (en) | 2010-12-15 | 2014-03-18 | General Electric Company | Restraint system for an energy storage device |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE |
CN110236526B (zh) * | 2019-06-28 | 2022-01-28 | 李秋 | 基于咀嚼吞咽动作及心电活动的摄食行为分析和检测方法 |
WO2024026423A1 (en) * | 2022-07-27 | 2024-02-01 | Black Diamond Therapeutics, Inc. | Substituted quinoline derivatives as pi3k inhibitors |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01211581A (ja) | 1988-02-18 | 1989-08-24 | Meiji Seika Kaisha Ltd | シクロペンテノピリジン誘導体および抗潰瘍剤 |
US4985352A (en) | 1988-02-29 | 1991-01-15 | The Trustees Of Columbia University In The City Of New York | DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof |
US5019574A (en) | 1988-09-30 | 1991-05-28 | Chugai Seiyaku Kabushiki Kaisha | 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function |
US5021421A (en) | 1989-03-03 | 1991-06-04 | Dainippon Pharmaceutical Co., Ltd. | 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same |
JP2660086B2 (ja) | 1990-07-03 | 1997-10-08 | 明治製菓株式会社 | 脳及び心機能障害改善剤 |
JPH04103572A (ja) | 1990-08-20 | 1992-04-06 | Dainippon Pharmaceut Co Ltd | 4―フェニル―2―(1―ピペラジニル)ピリジン誘導体 |
EP0572863A1 (de) | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
DE4326151A1 (de) | 1993-08-04 | 1995-02-09 | Hoechst Ag | Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
TW270114B (es) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
TW334423B (en) | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
US5698766A (en) | 1995-04-05 | 1997-12-16 | The Regents Of The University Of California | Transgenic animal model for testing drugs for treating eating disorders and epilepsy |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
JP3560986B2 (ja) | 1997-01-13 | 2004-09-02 | 山之内製薬株式会社 | 5―ht2c受容体作用薬及びアミノアルキルインダゾール誘導体 |
ES2208812T3 (es) | 1997-02-25 | 2004-06-16 | Akzo Nobel N.V. | Derivados de azetidina y de pirrolidina. |
US6322738B1 (en) | 1997-07-24 | 2001-11-27 | Husky Injection Molding Systems Ltd. | Method of injection over-molding articles |
US6040448A (en) | 1997-10-24 | 2000-03-21 | Neurogen Corporation | Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands |
CA2308057A1 (en) | 1997-10-24 | 1999-05-06 | Neurogen Corporation | 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d4 receptor subtype ligands |
AU4037699A (en) | 1998-05-08 | 1999-11-29 | Akzo Nobel N.V. | Novel aryl-hydro naphthalenal kanamines |
GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
GB9819019D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9819020D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds III |
AU754204B2 (en) | 1998-09-01 | 2002-11-07 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
JP2000191533A (ja) | 1998-10-19 | 2000-07-11 | Eisai Co Ltd | 鎮痛剤 |
AU1738900A (en) | 1998-11-19 | 2000-06-05 | Nortran Pharmaceuticals Inc. | Serotonin ligands as pro-erectile compounds |
JP2002535396A (ja) | 1999-01-27 | 2002-10-22 | イーライ・リリー・アンド・カンパニー | セロトニン(5−ht(2c))アゴニストとしてのアミノアルキルベンゾフラン類 |
EA005820B1 (ru) | 1999-05-21 | 2005-06-30 | Биовитрум Аб | Агонисты и антагонисты рецепторов 5-ht |
JP5218713B2 (ja) * | 2000-07-28 | 2013-06-26 | 住友ベークライト株式会社 | 光学導波管を形成するためのポリマー組成物;それらから形成される光学導波管;およびそれを作製するための方法 |
SE0004245D0 (sv) * | 2000-11-20 | 2000-11-20 | Pharmacia Ab | Novel compounds and their use |
IL155702A0 (en) | 2000-11-20 | 2003-11-23 | Biovitrum Ab | Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor |
TWI245761B (en) | 2001-03-01 | 2005-12-21 | Telik Inc | Antagonists of MCP-1 function and methods of use thereof |
EP1385823B1 (en) | 2001-04-09 | 2006-12-13 | Chiron Corporation | Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
EP1613322A4 (en) | 2003-04-11 | 2008-08-13 | Taigen Biotechnology Co Ltd | AMINOQUINOLINE COMPOUNDS |
US7101881B2 (en) | 2003-06-11 | 2006-09-05 | Pfizer Inc | Tetrahydroquinolines |
WO2006015263A2 (en) | 2004-07-29 | 2006-02-09 | Threshold Pharmaceuticals, Inc. | Lonidamine analogs |
-
2006
- 2006-03-21 MX MX2007012082A patent/MX2007012082A/es active IP Right Grant
- 2006-03-21 JP JP2008503608A patent/JP4318744B2/ja not_active Expired - Fee Related
- 2006-03-21 CA CA2602348A patent/CA2602348C/en not_active Expired - Fee Related
- 2006-03-21 BR BRPI0609268-3A patent/BRPI0609268A2/pt not_active IP Right Cessation
- 2006-03-21 WO PCT/IB2006/000655 patent/WO2006103511A1/en not_active Application Discontinuation
- 2006-03-21 EA EA200701853A patent/EA200701853A1/ru unknown
- 2006-03-21 EP EP06710585A patent/EP1869000A1/en not_active Withdrawn
- 2006-03-21 KR KR1020077022374A patent/KR100894006B1/ko not_active IP Right Cessation
- 2006-03-21 AU AU2006228378A patent/AU2006228378A1/en not_active Abandoned
- 2006-03-21 NZ NZ560917A patent/NZ560917A/en not_active IP Right Cessation
- 2006-03-21 AP AP2007004144A patent/AP2007004144A0/xx unknown
- 2006-03-28 PE PE2006000343A patent/PE20061333A1/es not_active Application Discontinuation
- 2006-03-29 AR ARP060101218A patent/AR054021A1/es unknown
- 2006-03-29 GT GT200600128A patent/GT200600128A/es unknown
- 2006-03-30 DO DO2006000076A patent/DOP2006000076A/es unknown
- 2006-03-30 UY UY29446A patent/UY29446A1/es not_active Application Discontinuation
- 2006-03-30 TW TW095111125A patent/TW200722423A/zh unknown
- 2006-03-30 NL NL1031473A patent/NL1031473C2/nl not_active IP Right Cessation
- 2006-03-31 US US11/395,327 patent/US7507732B2/en not_active Expired - Fee Related
-
2007
- 2007-08-23 IL IL185492A patent/IL185492A0/en unknown
- 2007-08-27 NO NO20074368A patent/NO20074368L/no not_active Application Discontinuation
- 2007-09-19 CR CR9386A patent/CR9386A/es not_active Application Discontinuation
- 2007-09-28 MA MA30262A patent/MA29354B1/fr unknown
- 2007-09-28 TN TNP2007000367A patent/TNSN07367A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200722423A (en) | 2007-06-16 |
IL185492A0 (en) | 2008-01-06 |
US20060247254A1 (en) | 2006-11-02 |
MX2007012082A (es) | 2007-11-20 |
AU2006228378A1 (en) | 2006-10-05 |
TNSN07367A1 (fr) | 2008-12-31 |
US7507732B2 (en) | 2009-03-24 |
EP1869000A1 (en) | 2007-12-26 |
PE20061333A1 (es) | 2007-01-13 |
MA29354B1 (fr) | 2008-03-03 |
NL1031473C2 (nl) | 2007-03-19 |
KR100894006B1 (ko) | 2009-04-17 |
JP4318744B2 (ja) | 2009-08-26 |
GT200600128A (es) | 2007-03-29 |
DOP2006000076A (es) | 2006-11-30 |
JP2008534568A (ja) | 2008-08-28 |
NO20074368L (no) | 2007-09-21 |
KR20070107183A (ko) | 2007-11-06 |
NL1031473A1 (nl) | 2006-10-03 |
WO2006103511A1 (en) | 2006-10-05 |
UY29446A1 (es) | 2006-10-31 |
CA2602348A1 (en) | 2006-10-05 |
CA2602348C (en) | 2011-03-01 |
EA200701853A1 (ru) | 2008-08-29 |
NZ560917A (en) | 2011-01-28 |
AP2007004144A0 (en) | 2007-08-31 |
AR054021A1 (es) | 2007-05-30 |
BRPI0609268A2 (pt) | 2010-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR9386A (es) | Derivados de ciclopentapiridina y tetrahidroquinolina | |
PA8657501A1 (es) | Derivados de piperida y su uso como agentes antiinflamatorios | |
CU20110078A7 (es) | Compuestos de carbazol | |
CY1114277T1 (el) | ΕΝΩΣΕΙΣ ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΥΠΟΔΟΧΕΑ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ | |
CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
CR7168A (es) | Ligandos del receptor de 5.ht y sus usos | |
UY31166A1 (es) | Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica | |
ECSP055967A (es) | N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos | |
CR10607A (es) | Derivado heterociclico fusionado y su uso | |
UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
NO20054856D0 (no) | 4-anilo-kinazolinderivater som antiproliferative midler | |
UY31127A1 (es) | Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841 | |
ECSP088145A (es) | Derivados bicíclicos como inhibidores de la cinasa p38 | |
UY29478A1 (es) | Compuestos heteroaromaticos acilaminobiciclicos y sus usos | |
ECSP109942A (es) | Nuevos herbicidas | |
BRPI0814772A2 (pt) | Indazóis substituídos por 5-piridinona | |
CR7566A (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6 | |
NI200900183A (es) | Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer. | |
ECSP099046A (es) | Derivados ciclopropil amina | |
UY31689A1 (es) | Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica | |
UY30534A1 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii | |
CO6280532A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
ECSP10010379A (es) | Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina | |
UY29733A1 (es) | Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotrópicos | |
UY29631A1 (es) | Derivados del 4,5-diarilpirrol, su preparación y su aplicación en terapéutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |